Shire's new CEO wasted no time in putting his stamp on the company's global operations. In his first quarterly report this morning the newly minted Chief Executive Flemming Ornskov divvied up the marketing operations among five units based on disease categories and forged a single R&D organization for the company.
Controlled drugs must be approved by the FDA, but also require a manufacturer that has been vetted by the Drug Enforcement Agency (DEA). Contract manufacturer Cedarburg Hauser Pharmaceuticals had one plant approved and just snagged approval for a second.
Federal authorities were interested in the way Shire was pushing many of its drugs and the company has now disclosed that an agreement is close. It said it will take a $57.5 million charge to its fourth-quarter earnings to settle up for its missteps.
Have a look at our top 10 2012 VC investment list for the diagnostics industry, based on the MoneyTree report and the Thomson Reuters data that helped inform it. It follows our look at the top 10 medical device venture investments from 2012 . Check out the list >>
Pfizer has launched Quillivant XR (controlled-release methylphenidate hydrochloride) for the treatment of ADHD. This is the first once-daily, extended-release liquid methylphenidate for ADHD available in the U.S.
Shire CEO Angus Russell's 13-year stint at the helm has provided a classic case study on how to efficiently build a biotech company.
Pfizer has gained access to the U.S.' first once-daily liquid attention deficit hyperactivity disorder (ADHD) treatment by acquiring NextWave Pharmaceuticals in a deal that could be worth up to $680 million.
The company will fork over $255 million up front, and up to $425 million in milestone payments, provided the new drug meets sales goals.
Pfizer ($PFE) has snapped up NextWave, the maker of a recently approved liquid ADHD drug, in a deal worth up to $680 million. The company will fork over $255 million up front, and up to $425 million in milestone payments, provided the new drug meets sales goals.
Novartis Venture Fund has stepped up to spearhead a $7 million A1 round for the Cambridge, MA-based startup Neurovance. The fledgling biotech was spun out of Euthymics Bioscience under the same management group to handle the development of a new drug for adult attention deficit hyperactivity disorder and a pipeline of central nervous system prospects.